-
Mashup Score: 0
Original Article from The New England Journal of Medicine — Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Source: www.nejm.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
At the 2023 World Congress on Gastrointestinal Cancers, Lucjan Wyrwicz discusses the extended benefit of pembrolizumab plus chemotherapy when evaluating outcomes on next-line therapy for advanced HER2-negative, gastric/gastroesophageal junction adenocarcinoma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the 2023 World Congress on Gastrointestinal Cancers, Lucjan Wyrwicz, MD, presented additional data from KEYNOTE-859. Learn more here: https://t.co/dobpUGb3gR #onctwitter #medtwitter #pembrolizumab https://t.co/fWdIcjPPwK
-
-
Mashup Score: 0Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas - 9 month(s) ago
The PD-1 inhibitor pembrolizumab displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The PD-1 inhibitor #pembrolizumab displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes. #oncology #medtwitter https://t.co/grjuFgJqjS https://t.co/NLWsn1cY4O
-
-
Mashup Score: 0Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas - 9 month(s) ago
The PD-1 inhibitor pembrolizumab displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The PD-1 inhibitor #pembrolizumab displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes. #oncology #medtwitter https://t.co/Y6zYjUF0eo
-
-
Mashup Score: 2Frontline Use of Pembrolizumab With Lenvatinib Supported in nccRCC - 9 month(s) ago
As the first study of its kind, KEYNOTE-B61 has demonstrated potential to move pembrolizumab plus lenvatinib earlier in the treatment of non-clear cell renal cell carcinoma.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Pembrolizumab given in combination with #lenvatinib has demonstrated durable antitumor efficacy in patients with non-clear cell renal cell carcinoma in the KEYNOTE-B61 study. #kcsm | @AlbigesL @GustaveRoussy https://t.co/r7na4nJaA5
-
-
Mashup Score: 0EV Plus Pembrolizumab Demonstrates High cORR, Durable Responses in Cisplatin-Ineligible Patients With mUC - 9 month(s) ago
There are limited first-line (1L) treatment options for patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy, and improved therapies are needed. Enfortumab vedotin (EV) and pembrolizumab have shown a survival benefit as individual treatments in the second-line and la/mUC settings. Researchers recently published new data on cohort K of the EV-103 phase 1b/2 study that investigated EV alone or combined with pembrolizumab in cisplatin-ineligibl
Source: guoncologynow.comCategories: Latest Headlines, Partners & KOLsTweet-
Enfortumab vedotin and #pembrolizumab have shown a survival benefit as individual treatments in locally advanced and metastatic urothelial cancer, but are they just as effective as a combination treatment? Read what new research has uncovered: https://t.co/4iaTYdEhNu https://t.co/NkQR45aTuD
-
-
Mashup Score: 0Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab - 9 month(s) ago
The incidence of uterine cancer and its associated mortality rate are increasing. This article reports key adverse reactions in patients with advanced endometri
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This report reviewed AEs from combination #lenvatinib + #pembrolizumab in patients with advanced #endometrialcancer (Study-309/KEYNOTE-775). Useful strategies: education, preventative measures/close monitoring, and dose modifications. #gyncsm @dchimd https://t.co/9lds7leVn8 https://t.co/XbV7D1ix5E
-
-
Mashup Score: 2Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170 - 10 month(s) ago
Key Points. Pembrolizumab monotherapy provides sustained antitumor activity in heavily pretreated R/R PMBCL.Complete responses were maintained after ∼4 years of
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#Hematology #Pembrolizumab in relapsed or refractory primary mediastinal large B-cell #lymphoma #PMBCL: final analysis of KEYNOTE-170 | @BloodJournal | American Society of Hematology @ASH_hematology #lymsm https://t.co/u2dY4mXYfu
-
-
Mashup Score: 1Wolters Kluwer Health - 10 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Perioperative #pembrolizumab given in combination with #chemotherapy prior to surgery and for up to one year as a single agent after surgery, led to significant improvement in event-free survival, says Heather Wakelee, MD, FASCO. https://t.co/gRMERZFzXU @HwakeleeMD https://t.co/QoS3dgKc16
-
-
Mashup Score: 0Wolters Kluwer Health - 10 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a Phase II clinical trial of #pembrolizumab, investigators found that 42 percent of patients with metastatic #braincancer benefited from the therapy, with seven patients in the trial surviving longer than 2 years. @MGHCancerCenter #ASCO23. https://t.co/BOxiSySVpD https://t.co/HC3gNx62Q5
-
Perioperative #Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer Worth a read! 👉https://t.co/fhDmrIwduc